A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed Single-Dose Regimen, Multicenter Study to Assess the Efficacy and Safety of SR141716 in Obese Type 2 Diabetic Patients on Diet and Exercise Alone
Phase of Trial: Phase III
Latest Information Update: 15 Jun 2016
At a glance
- Drugs Rimonabant (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SOLO
- Sponsors Sanofi
- 21 Jul 2009 Planned number of patients changed from 306 to 321 as reported by ClinicalTrials.gov.
- 14 Nov 2008 Status changed from active, no longer recruiting to discontinued, as reported by sanofi-aventis.
- 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.